The price of Smegglutide in the United States is more than ten times that of Europe, and China is about to enter a price war
阿豆学长长ov
发表于 2024-6-15 19:05:57
271
0
0
The US Senate Committee on Health, Education, Labor, and Pensions announced on June 14th that Lars Fruergaard Jorgensen, CEO of Novo Nordisk, has agreed to voluntarily attend a hearing that will focus on why the price of GLP-1 drug company Megglutide in the United States is so high.
At present, the monthly treatment cost of Novo Nordisk's Wegovy weight-loss drug Smegglutide in the United States is as high as $1349, while the monthly treatment costs in Germany and the United Kingdom are $140 and $92, respectively. This means that American patients need to bear the price of these drugs 10 to 15 times that of European patients.
Last month, Zhou Fude told reporters at a global media conference that the differences in drug pricing are caused by the differences in healthcare systems in different countries. When discussing whether GLP-1 drugs will be reduced in price with the entry of more competitors in the future, he said, "The price reduction of drugs is mainly achieved in different markets through medical insurance negotiations with the paying party, based on the value of the drugs, and reaching an agreement with the paying party on the price."
With the expansion of indications for Smegglutide, more indications beyond weight loss are expected to be covered by insurance, which is also a hot topic being actively evaluated by the US healthcare system.
The hearing is expected to be held in early September, during which Novo Nordisk will reveal more details about the pricing of drugs in different markets.
In China, the drug "Novotel", which is used by Novo Nordisk and Megglutide for the treatment of type 2 diabetes, has entered the medical insurance. The cost of 3ml dose is less than 800 yuan, which can be used for at least one month, about 100 dollars per month, and is in a lower price range globally.
As the patent for Smegglutide is about to expire in 2026, at least ten Chinese generic drugs are currently in the clinical stage. This week, New Beijiang Pharmaceutical, a subsidiary of Lizhu Group Holdings, became the second Chinese pharmaceutical enterprise to obtain the approval and acceptance of smeglutide diabetes generic drug from the State Food and Drug Administration.
In April of this year, Hangzhou Jiuyuan Genetic Engineering Co., Ltd. submitted an application for the listing of Simeglutide injection "Jiyoutai", which was accepted; Shijiazhuang Pharmaceutical Group also said last month that it is expected that Smeaglutide, which is used to treat diabetes, will be approved in 2026.
At present, specific clinical data for these generic drugs have not been released, but some companies have completed phase III clinical trials. Lizhu Group stated that it has invested over 140 million yuan in the drug development of Smegglutide.
Last year, the sales of Novo Nordisk's Novo Nordisk in China more than doubled, reaching 4.8 billion Danish kroner (approximately 700 million US dollars), accounting for 5% of the total global sales of the drug. The company told China Business News that it is seeking the approval of the weight loss indication of Smeglutide in Chinese Mainland and is expected to be listed later this year.
Karan Verma, medical research and data analyst of Clarivate, an information service provider, said in a report that Smeaglutide has achieved unprecedented success in Chinese Mainland. With the patent expiration approaching, Chinese pharmaceutical companies are accelerating to seize the generic drug market.
Analysts also say that if these generic drug products are proven to be as safe and effective as Novo Nordisk's Smegglutide drug, they will increase competition and lower overall market prices. Goldman Sachs analysts estimated in a report last year that generic drugs could lead to a decrease of about 25% in the price of Smegglutide in China.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- A century old battle between Chicago Stock Exchange and Trump's close friends over the US treasury bond bond market
- European investment giant JAB acquires 86 million shares of JDE Peet's held by Mondelez International
- BeiGene BeiZeAn receives positive feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use
- Musk claims that only two car companies in the United States have not gone bankrupt, and the future of the American version of "NIO" is worrying
- 49 people in the United States fell ill and 1 person died from consuming a McDonald's burger
- Foreign media: 49 people in the United States fell ill and 1 person died from eating a McDonald's burger
- The world is holding its breath in anticipation of the US election: 'Trump 2.0' is troubling economic leaders around the world!
- JD Seven Fresh responds to price war rumors: no one targeted, just offering low prices
- What major changes will the US technology industry face as the Trump 2.0 era approaches?
- Mid game battle of Double 11: The ebb of the "price war" and the shift of busy and idle merchants
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 3 小时前
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 前天 19:48
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 前天 20:09
- 支持
- 反对
- 回复
- 收藏
-
百度创始人李彦宏19日在2024中国5G+工业互联网大会上发表演讲时表示,多智能体协作应用无代码工具"秒哒"发布不到3天,超过5000家企业排队申请测试。此外,L4级端到端的自动驾驶大模型发布后,搭载百度这一大模 ...
- laozhucn
- 3 天前
- 支持
- 反对
- 回复
- 收藏